Harvard Stem Cell Institute researcher George Q. Daley, MD, PhD, also associate director of the Stem Cell Program at Children’s Hospital Boston, and HSCI colleagues Konrad Hochedlinger and Chad Cowan have produced a robust new collection of disease-specific stem cell lines, all of which were developed using the new induced pluripotent stem cell (iPS) technique. The paper is being published in the August 6 on-line edition of the journal Cell.
The new iPS lines, developed from the cells of patients ranging in age from one month to 57-years-old and suffering from a range of conditions from Down Syndrome to Parkinson’s disease, will be deposited in a new HSCI “core” facility being established at Massachusetts General Hospital (MGH), HSCI co-director Doug Melton announced yesterday. The operations of the iPS Core will be overseen by a faculty committee, which Daley will chair.
The cell lines the researchers produced carry the genes or genetic components for 10 different diseases, including Parkinson’s Disease, Type I diabetes, Huntington’s Disease, Down Syndrome, a form of combined immunodeficiency (“Bubble Boy’s Disease”), Lesch-Nyhan syndrome, Gaucher’s Disease, and two forms of Muscular Dystrophy, among others.
“We wanted to produce a large number of disease models for ourselves, our collaborators, and the stem cell research community to accelerate research,” Daley said. “The original embryonic stem cell lines are generic, and allow you to ask only basic questions. But these new lines are valuable tools for attacking the root causes of disease. Our work is just the beginning for studying thousands of diseases in a petri dish,” he said.
Melton said that the HSCI iPS Core will serve as a repository for iPS cells produced by HSCI scientists. “The Core will also function as a technical laboratory to produce these disease- specific lines for use by scientists around the world,” Melton said. He went on to say that “the suite of iPS cell lines reported by the Daley group marks an important achievement and a very significant advance for patients suffering from degenerative diseases.
These disease-specific iPS cells are invaluable tools that will allow researchers to watch the development diseases in petri dishes, outside of the patients. And we have good reason to believe that this will make it possible to find new treatments, and eventually drugs, to slow or even stop the course of a number of diseases. In years ahead,” Melton said, “this report will be seen as opening the door to a new approach to develop therapies."
"One of our goals in creating the NIH Director's Pioneer Award programs was to enable exceptionally creative scientists to move quickly in promising new directions, thereby speeding the intellectual and technical breakthroughs needed to address major challenges in biomedical or behavioral research," said National Institutes of Health Director Elias A. Zerhouni, M.D. "This is certainly the case for Drs. Daley and Hochedlinger, who deployed their Director's award resources to advance our ability to use induced pluripotent stem cells for disease-specific studies and drug development."
Daley and his colleagues, led by first-author and Children’s researcher In Hyun Park, PhD, intentionally produced some stem cell lines for highly heritable, single-gene diseases, such as Gaucher’s; complex genetic syndromes, such as Down; and then complex diseases, such as Parkinson’s, that involve genetic, cellular, and perhaps environmental components.
“The cell lines available from the iPS Core will allow stem cell researchers around the world to explore possible gene therapies for some conditions, and will aid in the development of drugs for others,” Daley said.
While Daley, President of the International Society for Stem Cell Research, is enthusiastic about the promise of reprogramming studies, he is far from ready to abandon experiments with embryonic stem cells. Daley believes that reprogramming and ESC research must advance in tandem to bring cell therapy to the clinic as quickly as possible.
The study was supported by grants from the National Institutes of Health (NIH), an NIH Director's Pioneer Award of the NIH Roadmap for Medical Research, an NIH Innovator’s Award, the Burroughs Wellcome Fund, the Leukemia and Lymhoma Society, the Harvard Stem Cell Institute, Children’s Hospital Boston Stem Cell Program, the Stowers Medical Institute, and the Howard Hughes Medical Institute.
Scientists unlock ability to generate new sensory hair cells
22.02.2017 | Brigham and Women's Hospital
New insights into the information processing of motor neurons
22.02.2017 | Max Planck Florida Institute for Neuroscience
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
22.02.2017 | Power and Electrical Engineering
22.02.2017 | Life Sciences
22.02.2017 | Physics and Astronomy